

17 April 2026

*Not for release to US wire services or distribution in the United States*

## Completion of Security Purchase Plan

**Philadelphia PA and Phoenix AZ, 17 April 2026:** Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), advises that its security purchase plan (**SPP**) offered under the prospectus lodged with ASIC and released to the ASX on Wednesday, 11 March 2026 (**Prospectus**), closed on Monday, 13 April 2026. The SPP was underwritten up to A\$5 million by Euroz Hartleys Limited and Canaccord Genuity (Australia) Limited (together, the **Joint Lead Managers**).

The Company advises that it received valid applications for 14,341,646 fully paid ordinary shares in the Company (**New Shares**) at an issue price of A\$0.06 per New Share to raise A\$860,500 (before costs) under the SPP. The Company also offered participants in the SPP options on a 1:1 basis for New Shares issued under the SPP (**New Options**) exercisable at A\$0.06 each on or before 31 January 2027. The New Shares and New Options together comprise the **New Securities**.

As the total valid applications received under the SPP were below the underwritten amount of A\$5 million, there was a shortfall of A\$4,139,500 under the SPP (**SPP Shortfall**). The SPP Shortfall will be taken up by the Joint Lead Managers and/or the sub-underwriters (**Sub-underwriters**) in accordance with the Underwriting Agreement. The Joint Lead Managers and/or Sub-underwriters allocated New Shares under the SPP Shortfall will also receive corresponding New Options on a 1:1 basis and one (1) New Option for every three (3) New Shares allocated under the SPP Shortfall (**Sub-underwriter Options**) as part of the fees for the underwriting on the terms set out in the Prospectus.

Accordingly, the Company will raise the underwritten amount of A\$5 million under the SPP (before costs). The allocation of New Securities under the SPP Shortfall will be determined by the Joint Lead Managers in consultation with the Company, in accordance with the terms of the Underwriting Agreement.

The SPP was announced on Tuesday, 17 February 2026, in connection with a non-underwritten two-tranche Placement offering New Shares at A\$0.06 each to new and existing professional and sophisticated investors to raise approximately A\$40 million (before costs) (**Placement**).

Together with the Placement, the Company has raised a total of A\$45 million (before costs) from the issue of New Shares under the SPP and the Placement, which will be used to fund Active Pharmaceutical Ingredient (**API**) purchases and manufacturing components, alternate API supplier setup, advertising and marketing initiatives, Opex and working capital, and capital raising costs.

The New Securities under the SPP (including the SPP Shortfall), the Sub-underwriter Options and the New Options under the Placement, which were approved by shareholders at its general meeting held on 1 April 2026, will be issued on Monday, 20 April 2026. The New Shares are expected to commence trading on ASX on Tuesday, 21 April 2026.

For personal use only

The Company would like to thank all participating shareholders for their support.

This ASX release was authorised on behalf of the Botanix Pharmaceuticals Ltd Board of Directors by:

**Vince Ippolito**

Executive Chairman

**About Botanix Pharmaceuticals**

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. Sofdra is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: <http://www.botanixpharma.com/>

**For more information, please contact:**

General enquiries  
Corporate Communications  
Botanix Pharmaceuticals  
P: +61 8 6285 0083  
[info@botanixpharma.com](mailto:info@botanixpharma.com)

Investor enquiries  
Hannah Howlett  
P: +61 4 5064 8064  
[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

Media enquiries  
Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)

**Cautionary Note on Forward-Looking Statements**

Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra* and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.